Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL1978104 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL6465998 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41204 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL4016537 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8025793 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL2412146 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL7204032 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18948 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41203 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18949 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| WO-2024088808-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2024-05-02 | — | — | WO | claimed |
| US-20240122877-A1 | ORAL AMPHETAMINE COMPOSITION | ADARE PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | claimed |
| US-20240052404-A1 | SYSTEMS AND METHODS FOR IMMUNOFLUORESCENCE QUANTIFICATION | 10X GENOMICS, INC. | 2024-02-15 | — | — | US | claimed |
| WO-2024036191-A1 | SYSTEMS AND METHODS FOR COLOCALIZATION | 10X GENOMICS, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| US-11896562-B2 | Oral amphetamine composition | ADARE PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | claimed |
| WO-2024031068-A1 | SYSTEMS AND METHODS FOR IMMUNOFLUORESCENCE QUANTIFICATION | 10X GENOMICS, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230394790-A1 | SYSTEMS AND METHODS FOR IDENTIFYING MORPHOLOGICAL PATTERNS IN TISSUE SAMPLES | 10X GENOMICS, INC. | 2023-12-07 | — | — | US | claimed |
| CN-117036248-A | System and method for identifying morphological patterns in tissue samples | 10X基因组学有限公司 | 2023-11-10 | — | — | CN | claimed |
| WO-2023212532-A1 | SYSTEMS AND METHODS FOR EVALUATING BIOLOGICAL SAMPLES | 10X GENOMICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-1202739-A4 | RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM | SHIRE LAB INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (BM) | 2003-10-16 | — | — | US | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| EP-1202739-A1 | RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM | Shire Laboratories Inc. (US) | 2002-05-08 | — | — | EP | claimed |
| US-6384020-B1 | AMPHETAMINE BASE AND LACTITOL WITH MICROCRYSTALLINE CELLULOSE | SHIRE LABORATORIES, INC. | 2002-05-07 | — | — | US | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| WO-2001005407-A1 | RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM | SHIRE LABORATORIES, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.